Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream).

Abstract

Background:  Acne vulgaris is a disorder of the pilo-sebaceous unit in which the androgens contribute to its onset and persistence. The use of anti-androgens is therefore potentially effective, however anti-androgens for topical use are not available in the market. Cortexolone 17α-propionate (CB-03-01) is a new potent topical anti-androgen potentially useful in acne vulgaris.


Objectives:  To evaluate the safety and the topical efficacy of cortexolone 17α-propionate 1% cream in acne vulgaris as compared to placebo and to tretinoin (Retin-A® 0.05% cream).


Patients/Methods:  Seventy-seven adult males with facial acne scored 2-3 according to Investigator’s ...

Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream). is a post from: Skincare

Cortexolone 17α-propionate 1% cream, a new potent anti-androgen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study versus placebo and tretinoin (Retin-A® 0.05% cream). via BuzzBlazer.com